Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11476145 | 0.77 | LMNA (0.74) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL2949601 | 0.75 | — | — | |
| SCHEMBL6706926 | 0.73 | — | — | |
| SCHEMBL95982 | 0.72 | TSHR (1.00) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| Selenium SCHEMBL30845448 | 0.69 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL30845449 | 0.69 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| Water SCHEMBL11221867 | 0.69 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL1498152 | 0.69 | — | — | |
| Ammonia Solution, Strong SCHEMBL8958644 | 0.69 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL10457214 | 0.69 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124757-B2 | Thiol-modified macromolecule derivatives and cross-linked materials thereof | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2012-02-28 | — | — | US | disclosed |
| US-20100152423-A1 | THIOL-MODIFIED MACROMOLECULE DERIVATIVES AND CROSS-LINKED MATERIALS THEREOF | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152423-A1 | THIOL-MODIFIED MACROMOLECULE DERIVATIVES AND CROSS-LINKED MATERIALS THEREOF | PTMS, TMT1A, EPCAM | TSHR 863/4885LMNA 3917/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.